EP Wealth Advisors LLC increased its holdings in Humana Inc. (NYSE:HUM – Free Report) by 1.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,294 shares of the insurance provider’s stock after purchasing an additional 37 shares during the quarter. EP Wealth Advisors LLC’s holdings in Humana were worth $1,050,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds have also added to or reduced their stakes in HUM. Neo Ivy Capital Management bought a new stake in shares of Humana in the 4th quarter valued at about $952,000. V Square Quantitative Management LLC lifted its position in Humana by 36.6% in the fourth quarter. V Square Quantitative Management LLC now owns 2,022 shares of the insurance provider’s stock valued at $926,000 after purchasing an additional 542 shares during the last quarter. Quarry LP lifted its position in Humana by 195.2% in the fourth quarter. Quarry LP now owns 124 shares of the insurance provider’s stock valued at $57,000 after purchasing an additional 82 shares during the last quarter. Aurora Investment Counsel boosted its stake in shares of Humana by 1.3% during the fourth quarter. Aurora Investment Counsel now owns 2,273 shares of the insurance provider’s stock valued at $1,155,000 after purchasing an additional 29 shares during the period. Finally, PARUS FINANCE UK Ltd grew its holdings in shares of Humana by 2.3% in the fourth quarter. PARUS FINANCE UK Ltd now owns 10,923 shares of the insurance provider’s stock worth $5,001,000 after purchasing an additional 250 shares during the last quarter. 92.38% of the stock is owned by institutional investors.
Humana Price Performance
HUM opened at $355.41 on Tuesday. The firm has a market cap of $42.83 billion, a PE ratio of 22.13, a P/E/G ratio of 2.10 and a beta of 0.52. The stock has a 50-day moving average price of $337.10 and a 200-day moving average price of $358.26. Humana Inc. has a 1 year low of $298.61 and a 1 year high of $530.54. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.67 and a quick ratio of 1.67.
Humana Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be paid a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.00%. The ex-dividend date is Friday, June 28th. Humana’s dividend payout ratio is currently 22.04%.
Wall Street Analyst Weigh In
Several equities research analysts have weighed in on the stock. Barclays dropped their price target on shares of Humana from $356.00 to $310.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 2nd. Bank of America raised their target price on Humana from $342.00 to $376.00 and gave the stock a “neutral” rating in a research note on Monday, May 20th. Jefferies Financial Group lowered their price target on Humana from $411.00 to $381.00 and set a “buy” rating for the company in a research report on Monday, April 22nd. Royal Bank of Canada cut their price objective on Humana from $415.00 to $353.00 and set an “outperform” rating on the stock in a research report on Thursday, April 25th. Finally, Oppenheimer dropped their price target on Humana from $415.00 to $370.00 and set an “outperform” rating for the company in a research note on Thursday, April 25th. Thirteen equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, Humana presently has a consensus rating of “Hold” and an average target price of $423.63.
Check Out Our Latest Analysis on HUM
About Humana
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Further Reading
- Five stocks we like better than Humana
- 5 Top Rated Dividend Stocks to Consider
- Buffett Bails on BYD: What It Means for the Future of EV Stocks
- How to Invest in Insurance Companies: A Guide
- Domino’s vs. Papa John’s: Stock Showdown of Pizza Giants
- How to invest in marijuana stocks in 7 steps
- Williams-Sonoma Makes Stock More Accessible with a Stock Split
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.